Tesamorelin: The only FDA-approved growth hormone secretagogue — designed for HIV lipodystrophy, now chased for visceral fat reduction and cognitive benefit off-label

Tesamorelin occupies a unique position in the Growth Hormone Secretagogues cluster: it is the only compound with FDA approval. While other GHRH analogs and ghrelin mimetics in this cluster rely on Phase I data, community anecdote, or preclinical evidence, tesamorelin has two Phase III randomized controlled trials, regulatory review, and more than fifteen years of post-marketing surveillance behind it. That distinction matters, but it requires a careful qualifier — the FDA approved tesamorelin for one specific condition (HIV-associated lipodystrophy), and the off-label uses that drive most community interest operate on a different evidence footing.

Theratechnologies developed tesamorelin as a stabilized analog of human growth hormone-releasing hormone — the full 44-amino acid GHRH sequence with a hexenoyl modification at the N-terminus that protects against the enzyme (DPP-IV) that normally destroys GHRH in minutes. The result is a peptide that stimulates pulsatile growth hormone release through the body’s own pituitary machinery, preserving the feedback loops that prevent GH excess. That pharmacological elegance — stimulating GH through the body’s own signaling architecture rather than injecting GH directly — is the core appeal of GHRH analogs, and tesamorelin has the strongest clinical evidence that the approach works.

Understanding tesamorelin requires keeping the approved indication and the off-label landscape clearly distinguished. For visceral fat reduction in HIV lipodystrophy, the evidence is Phase III quality. For non-HIV body composition, liver fat reduction, and cognitive benefit, the evidence is Phase II or exploratory — meaningful, mechanistically coherent, and actively researched, but not at the level that earned the FDA approval. This article treats each evidence question on its own terms.

Quick Facts: Tesamorelin at a Glance

What Is Tesamorelin?

Your pituitary gland releases growth hormone in pulses — not a steady drip, but discrete bursts triggered by a 44-amino acid signal molecule called GHRH. That signal molecule has a problem: it survives in your bloodstream for less than ten minutes before an enzyme called DPP-IV chews off its first two amino acids and kills it. Tesamorelin is that signal molecule with one modification — a small chemical cap (trans-3-hexenoic acid) welded onto the vulnerable end, extending its working life from minutes to roughly half an hour. That’s enough time to trigger a physiologically patterned GH pulse from the pituitary before the body’s own feedback systems bring things back to baseline.

Structurally, tesamorelin retains the complete endogenous GHRH(1-44) amino acid sequence. This is a meaningful distinction from other GHRH analogs: sermorelin uses only the first 29 amino acids (a truncation that still binds the receptor but with potentially different pharmacodynamics), while CJC-1295 (no DAC) is a modified version of that same 1-29 fragment. Tesamorelin is the full molecule, minimally altered.

The mechanism begins at the GHRH receptor (GHRHR) on pituitary somatotroph cells. Tesamorelin binds GHRHR, activating a Gs protein → adenylyl cyclase → cAMP → PKA signaling cascade that triggers exocytosis of stored growth hormone granules. The resulting GH pulse enters the bloodstream and acts on target tissues — most relevantly, adipose tissue and the liver. In adipose tissue, GH activates hormone-sensitive lipase, driving lipolysis. Visceral adipose tissue has higher GH receptor density than subcutaneous fat, which is why tesamorelin preferentially reduces deep belly fat rather than fat everywhere equally.

Critically, the body’s feedback architecture remains intact. GH stimulates hepatic IGF-1 production, and rising IGF-1 feeds back to the hypothalamus and pituitary to suppress further GH release (somatostatin-mediated negative feedback). This self-regulating loop is what distinguishes GHRH analogs from exogenous GH injection, which bypasses the pituitary entirely and eliminates physiological regulation.

Tesamorelin was developed by Theratechnologies Inc. (Montreal, Canada) specifically to address HIV-associated lipodystrophy — a condition for which no approved treatment existed at the time of development.

Origins and FDA Approval History

The clinical problem that created tesamorelin was specific and urgent. By the early 2000s, antiretroviral therapy had transformed HIV from a death sentence into a manageable chronic condition — but lifelong ART came with metabolic consequences. A substantial proportion of HIV patients on antiretroviral drugs developed lipodystrophy: abnormal fat redistribution characterized by visceral fat accumulation, peripheral fat wasting, dyslipidemia, and insulin resistance. The visceral fat component was not cosmetic. It elevated cardiovascular risk, worsened metabolic syndrome, and in some patients reduced medication adherence because of visible body changes.

No approved treatment existed. Theratechnologies hypothesized that pulsatile GH stimulation through the GHRH receptor could selectively reduce visceral fat without the side effect profile of direct GH injection. They designed tesamorelin as a stabilized full-length GHRH analog and moved it into clinical development.

The Phase III program consisted of two pivotal randomized controlled trials. The first (Falutz et al., NEJM 2007, PMID: 18057338) enrolled 412 HIV-infected adults with lipodystrophy and VAT ≥130 cm² on CT scan. After 26 weeks, tesamorelin 2 mg SC daily reduced visceral adipose tissue by approximately 15% compared to a 5% increase in the placebo group. The second trial (Falutz et al., JAIDS 2010, PMID: 20101189) enrolled 406 patients and replicated the results. Across both trials, 69% of tesamorelin patients achieved a clinically meaningful response (≥8% VAT reduction) compared to 33% on placebo. Triglycerides improved by approximately 50 mg/dL in the treatment group.

The FDA approved tesamorelin on November 10, 2010 (NDA 022505) under the brand name Egrifta, for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Subsequent formulation improvements led to Egrifta SV (single-vial, 2019) and Egrifta WR (water-reconstituted, approximately 2024–2025).

An important feature of the Phase III extension data: patients who switched from tesamorelin to placebo saw visceral fat re-accumulate toward pre-treatment levels. The effect is not permanent. Ongoing daily injection is required to maintain the benefit, with implications for long-term cost (~$1,000–$1,500/month for brand Egrifta), injection burden, and cumulative safety exposure.

Mechanism of Action

Tesamorelin’s mechanism begins with a single receptor: the growth hormone-releasing hormone receptor (GHRHR), a G protein-coupled receptor expressed predominantly on pituitary somatotroph cells. When tesamorelin binds GHRHR, it activates a Gs protein that stimulates adenylyl cyclase, raising intracellular cAMP levels and activating protein kinase A (PKA). PKA phosphorylates targets that open calcium channels and trigger exocytosis of stored GH granules. The result is a discrete pulse of growth hormone released into the bloodstream.

DPP-IV Resistance

Endogenous GHRH is destroyed within minutes by dipeptidyl peptidase IV (DPP-IV), which cleaves the first two amino acids. Tesamorelin’s N-terminal hexenoyl cap blocks this cleavage site, extending the half-life from less than 10 minutes (endogenous GHRH) to approximately 26 minutes in healthy subjects and 38 minutes in HIV patients at steady state. The single-dose half-life is shorter (~8 minutes), with the steady-state extension reflecting tissue distribution kinetics.

Lipolytic Mechanism

The growth hormone released by tesamorelin acts on target tissues through the GH receptor (GHR). In adipose tissue, GH activates hormone-sensitive lipase (HSL), the primary enzyme responsible for triglyceride hydrolysis. Visceral adipose tissue expresses GH receptors at higher density than subcutaneous adipose tissue, which explains the preferential visceral fat reduction observed in clinical trials. This receptor density gradient means tesamorelin’s lipolytic effect is disproportionately targeted at the metabolically dangerous deep abdominal fat rather than subcutaneous fat under the skin.

Feedback and the IGF-1 Axis

GH released into the bloodstream acts on the liver to stimulate production of insulin-like growth factor 1 (IGF-1). Rising IGF-1 levels feed back to the hypothalamus and pituitary, activating somatostatin release and suppressing further GH secretion. This negative feedback loop is the key safety distinction between GHRH analogs and exogenous GH injection. Exogenous GH bypasses the pituitary entirely, eliminating the body’s ability to self-regulate GH levels. Tesamorelin works within the existing regulatory architecture.

Comparison to Other GH-Axis Compounds

vs. Sermorelin: Sermorelin uses only the first 29 amino acids of GHRH (a truncation). Tesamorelin retains the full 44-AA sequence and has a longer half-life (~26–38 min vs. ~10–20 min). Tesamorelin is the only GHRH analog with FDA approval and Phase III data. Whether these differences translate to clinically superior GH stimulation requires head-to-head data that does not yet exist.

vs. CJC-1295 (no DAC): A modified GHRH(1-29) fragment with different amino acid substitutions to resist proteolysis. Same receptor target (GHRHR), different modification strategy. No FDA approval, no Phase III data.

vs. CJC-1295 with DAC: The Drug Affinity Complex creates sustained GHRH receptor stimulation over 6–8 days, producing a non-pulsatile GH profile. This is fundamentally different from tesamorelin’s once-daily pulsatile release and may have different metabolic consequences.

vs. GHS-R1a agonists (ipamorelin, GHRP-6): These act on the ghrelin receptor (GHS-R1a), which uses a different signaling pathway (Gq/calcium vs. Gs/cAMP). Pharmacologically non-redundant with GHRHR agonists, which is why the community stacks tesamorelin with ipamorelin — though no clinical trial has studied this combination.

vs. Exogenous GH: Direct GH injection bypasses pituitary regulation entirely. It produces supraphysiological, non-pulsatile GH levels without somatostatin feedback. Different risk profile, different magnitude of effect, and significantly more regulatory burden.

The Approved Indication: HIV-Associated Lipodystrophy

HIV-associated lipodystrophy is a metabolic complication of long-term antiretroviral therapy characterized by abnormal fat redistribution: visceral fat accumulation in the trunk, peripheral fat wasting in the face and limbs, dyslipidemia, and insulin resistance. The visceral component is not cosmetic — it is associated with elevated cardiovascular risk, metabolic syndrome, and reduced quality of life. Before tesamorelin, no FDA-approved pharmacological treatment existed for this condition.

The Phase III program enrolled patients with documented HIV infection on stable antiretroviral therapy and visceral adipose tissue ≥130 cm² on CT scan. Results from the two pivotal trials were consistent:

Endpoint	Tesamorelin 2 mg	Placebo
VAT change at 26 weeks	−15.2%	+5.0%
Response rate (≥8% VAT reduction)	69%	33%
Triglyceride change	−50 mg/dL	+9 mg/dL
Combined enrollment	818 patients across 2 trials

A post-hoc analysis (PMC9947601) demonstrated that tesamorelin was equally effective in patients with and without dorsocervical fat accumulation (buffalo hump), extending the applicability within the lipodystrophy population.

Key Research Areas and Studies

NAFLD / Hepatic Steatosis (Phase II RCT)

Stanley TL et al. (Lancet HIV 2019, PMID: 31611038) conducted a randomized controlled trial of tesamorelin 2 mg daily in 61 HIV-infected patients with non-alcoholic fatty liver disease. After 12 months, tesamorelin reduced absolute hepatic fat fraction by 4.1 percentage points (P=0.02) — a 37% relative reduction. Thirty-five percent of tesamorelin patients dropped below the 5% hepatic fat threshold (no longer meeting NAFLD criteria) compared to just 4% on placebo. Perhaps more significant for long-term outcomes: only 2 of 26 tesamorelin patients showed fibrosis progression versus 8 of 28 placebo patients.

A hepatic transcriptomic sub-study (Stanley et al., JCI Insight 2020, PMID: 32701508) found that tesamorelin increased expression of oxidative phosphorylation genes while decreasing inflammatory and fibrosis gene sets, providing a mechanistic explanation for the clinical improvements.

Cognitive Function (Phase II RCT — Non-HIV Population)

Baker LD et al. (Arch Neurol 2012, PMID: 22869065) conducted a 20-week randomized controlled trial giving tesamorelin 1 mg daily (lower than the approved 2 mg dose) to 152 non-HIV adults aged 55–87 — 66 with mild cognitive impairment and 86 cognitively healthy. Executive function improved significantly (P=0.005), and verbal memory showed a positive trend (P=0.08). IGF-1 increased 117% and body fat decreased 7.4%.

A follow-up GABA sub-study (PMID: 23689947) found that tesamorelin increased brain GABA levels and decreased myo-inositol in the posterior cingulate cortex — neurochemical changes consistent with the cognitive improvements observed. This is one of the most mechanistically coherent cognitive-enhancement applications among research peptides.

Muscle Composition

Erlandson KM et al. (J Frailty Aging 2019, PMID: 31237318) conducted a secondary analysis of Phase III data examining 193 tesamorelin responders and 148 placebo patients. Tesamorelin increased truncal muscle density (+1.56 to +4.86 HU) and muscle area (+0.64 to +1.08 cm²). This is exploratory data from a secondary analysis, but it extends the GH body composition picture beyond fat reduction alone.

Non-HIV Body Composition — The Evidence Gap

No published Phase II or Phase III randomized controlled trial exists for tesamorelin in non-HIV overweight or obese adults. This is a critical gap between the evidence base and how tesamorelin is actually used. Community use and off-label clinical prescribing for general visceral fat reduction is widespread. One active trial — NCT06554717, studying tesamorelin as an adjunct to exercise — is registered but not yet published.

The mechanistic plausibility is strong: GHRHR is not HIV-specific, and GH-mediated visceral fat lipolysis should work in any population with functional pituitary somatotrophs. But plausibility is not proof. The evidence for non-HIV body composition use is extrapolation from HIV trials plus clinical observation, not controlled trial data. This article reflects that distinction honestly.

Common Claims versus What the Evidence Shows

Claim	What the Evidence Shows	Verdict
Tesamorelin reduces abdominal fat in HIV patients with lipodystrophy	FDA-approved: two Phase III RCTs (combined n=818), ~15% VAT reduction, 69% response rate at ≥8% reduction.	Approved — Phase III
Tesamorelin reduces visceral fat in non-HIV adults	No published RCT in non-HIV adults. Mechanistic plausibility is strong (GHRHR is not HIV-specific). Off-label prescribing is common. One active clinical trial (NCT06554717) not yet published.	Mechanistically Plausible — No RCT
Tesamorelin reduces liver fat (NAFLD)	Phase II RCT in HIV+ adults (Stanley 2019, PMID 31611038): 37% relative hepatic fat reduction, 35% no longer met NAFLD criteria. Prevented fibrosis progression.	Phase II Supported
Tesamorelin improves cognitive function	Phase II RCT in NON-HIV older adults (Baker 2012, PMID 22869065): executive function improved (P=0.005), verbal memory trend (P=0.08). Mechanistically coherent (GH/IGF-1 axis + brain GABA).	Phase II — Promising
Tesamorelin improves muscle quality	Secondary analysis of Phase III data (Erlandson 2019, PMID 31237318): increased muscle density and area in HIV+ adults with VAT response.	Exploratory — Secondary Analysis
Tesamorelin reduces cardiovascular risk	VAT reduction is associated with triglyceride improvement in Phase III data. No direct cardiovascular outcome data exists. Risk reduction is inferred from metabolic markers, not proven.	Inferred — Surrogate Endpoints
Tesamorelin is equivalent to GH replacement for body recomposition	Incorrect. Tesamorelin acts through pituitary-regulated GH secretion with feedback constraints. Effects are not equivalent to supraphysiological exogenous GH. Different risk profile, different magnitude of effect.	Misleading
Tesamorelin is safe for long-term use	Post-marketing data spans 15+ years. Known risks (glucose impairment, IGF-1 elevation, fluid retention) are monitorable. Long-term IGF-1 elevation and theoretical cancer risk remain under surveillance.	Supported with Monitoring
Tesamorelin effects are permanent	Incorrect. VAT returns toward baseline after discontinuation. This is documented in Phase III extension data. Ongoing treatment required for maintenance.	Incorrect
Tesamorelin at 1 mg daily is as effective as 2 mg	The cognitive trial (Baker 2012) used 1 mg/day with positive results. The FDA-approved dose for VAT reduction is 2 mg/day. No head-to-head dose comparison exists for body composition endpoints.	Insufficient Data
Tesamorelin can be stacked with ipamorelin	This combines GHRHR agonism (tesamorelin) with GHS-R1a agonism (ipamorelin) — two different GH release pathways. Pharmacologically non-redundant. No clinical trial has studied this combination. Community practice exists.	Pharmacologically Coherent — No Trial Data
Tesamorelin is better than sermorelin	Tesamorelin retains full 44-AA sequence vs. sermorelin’s 1-29 truncation. Longer half-life. Only GHRH analog with FDA approval. Whether this translates to clinically superior GH stimulation requires head-to-head data that does not exist.	Plausible — No Head-to-Head Data

We currently don’t have any vetted partners for this compound. Check back soon.

The Human Evidence Landscape

Tesamorelin has the strongest evidence base among GHRH analogs by a substantial margin. For the approved indication of HIV-associated lipodystrophy, the evidence is unmatched in this compound class: two Phase III randomized controlled trials with objective CT-measured endpoints, regulatory review, FDA approval, and more than fifteen years of post-marketing surveillance data.

The off-label evidence landscape is more nuanced. The NAFLD trial (Stanley 2019) is Phase II quality in an HIV population — meaningful, especially with the mechanistic transcriptomic support, but not yet replicated or tested at Phase III scale. The cognitive function trial (Baker 2012) is particularly interesting because it was conducted in a non-HIV population (healthy aging adults and those with mild cognitive impairment), making it the most relevant data for the off-label community. The muscle composition data (Erlandson 2019) is exploratory, from secondary analysis of Phase III trial data.

The most significant evidence gap is the one most relevant to off-label users: no published RCT exists for tesamorelin in non-HIV adults for body composition. The mechanism should work (GHRHR is not HIV-specific), and off-label prescribing is widespread, but the published evidence base has not caught up with clinical practice. One active trial (NCT06554717) may eventually address this gap.

Safety, Risks, and Limitations

Established Safety Profile from Phase III and Post-Marketing

The Phase III program and subsequent post-marketing surveillance provide a well-characterized safety profile. The most common adverse events: injection site reactions (25% vs. 14% placebo), arthralgia, peripheral edema and fluid retention, myalgia, and peripheral sensory neuropathy (less common). Hypersensitivity reactions occurred in 4% of treated patients, with pruritus, erythema, flushing, and urticaria. Anti-tesamorelin IgG antibodies were detected in approximately 85% of hypersensitivity cases, with anti-GHRH cross-reactivity in ~60% of antibody-positive patients.

Glucose and Insulin

Growth hormone impairs insulin sensitivity — this is a class effect shared by all GH-releasing compounds. In Phase III trials, HbA1c ≥6.5% developed in 5% of tesamorelin patients versus 1% on placebo at 26 weeks. This is clinically relevant in HIV patients who are already at elevated metabolic risk from antiretroviral therapy. Glucose monitoring is required per the prescribing information.

Comparison to MK-677 is informative: MK-677’s continuous 24-hour GHS-R1a stimulation produces more sustained glucose elevation. Tesamorelin’s pulsatile GH profile allows insulin sensitivity to recover between pulses, which may produce less cumulative metabolic stress — though this has not been tested in a head-to-head trial.

IGF-1 Elevation

Growth hormone stimulates hepatic IGF-1 production. Sustained supraphysiological IGF-1 levels are associated, in epidemiological data, with increased cancer risk. The FDA-approved prescribing information recommends monitoring IGF-1 levels and considering discontinuation if they remain persistently elevated above 3 standard deviations. For prescribed Egrifta users, IGF-1 monitoring is standard of care. For off-label users without prescriber oversight, IGF-1 monitoring is the user’s responsibility — and it is non-negotiable.

Transient Effect — VAT Returns

Phase III extension data document that visceral fat re-accumulates toward pre-treatment levels after discontinuation. Ongoing daily injection is required to maintain the benefit. This has practical implications: cost (~$1,000–$1,500/month for brand Egrifta), injection burden, and cumulative safety exposure from sustained IGF-1 elevation.

Contraindications

Tesamorelin is contraindicated in patients with disrupted hypothalamic-pituitary axis (the mechanism requires a functional pituitary), active malignancy (GH/IGF-1 may promote tumor growth), pregnancy (Category X — teratogenic in animal studies), and hypersensitivity to tesamorelin or excipients.

Legal and Regulatory Status

FDA Status

Tesamorelin is FDA-approved under NDA 022505 (Egrifta, November 2010) for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. It is a prescription drug. Off-label prescribing by physicians for non-HIV patients is legal under standard medical practice. The formulation has evolved from the original Egrifta to Egrifta SV (single-vial, 2019) and Egrifta WR (water-reconstituted).

Research-grade tesamorelin from peptide vendors is not the FDA-approved Egrifta and is not subject to pharmaceutical quality standards. Compounding pharmacies can produce tesamorelin under 503A/503B rules for off-label prescriptions. The distinction between pharmaceutical-grade Egrifta and compounded or research-grade tesamorelin is relevant to purity, potency, and regulatory oversight.

WADA Status

International Status

Egrifta is approved in multiple countries for HIV-associated lipodystrophy. Regulatory status varies by jurisdiction for compounded and research forms. Tesamorelin is not a controlled substance in the United States; it is a prescription drug for the approved indication.

Dosing in Published Research

Study	Population	Dose	Duration	Key Findings
Falutz 2007 (PMID 18057338)	HIV+ lipodystrophy (n=412)	2 mg SC daily	26 wk + ext	−15% VAT vs. +5% placebo
Falutz 2010 (PMID 20101189)	HIV+ lipodystrophy (n=406)	2 mg SC daily	26 wk	Replicated results; basis for FDA approval
Stanley 2019 (PMID 31611038)	HIV+ with NAFLD (n=61)	2 mg SC daily	12 mo + 6 mo OL	−37% hepatic fat; 35% resolved NAFLD
Baker 2012 (PMID 22869065)	Non-HIV, MCI + healthy aging (n=152)	1 mg SC daily	20 wk + washout	Executive function ↑, verbal memory trend
Erlandson 2019 (PMID 31237318)	HIV+ (secondary analysis of Phase III)	2 mg SC daily	26–52 wk	Muscle density ↑, muscle area ↑

Dosing in Independent Self-Experimentation Communities

Parameter	Typical Community Range	Notes
Dose	1–2 mg/day; 2 mg most common	FDA-approved dose is 2 mg. Community generally follows clinical dose.
Frequency	Once daily SC injection	Evening dosing preferred (GH release timing synergy with sleep)
Injection site	Abdomen preferred	Per FDA prescribing information; rotate within general area
Cycle duration	8–12 weeks typical; some run continuously	Continuous use matches approved indication protocol
Timing	Empty stomach, 30 min before bedtime	GH blunted by carbs/fat; bedtime aligns with physiological GH pulse
Stacking	Commonly combined with ipamorelin	GHRHR + GHS-R1a dual-pathway; no clinical data on combination
Monitoring	IGF-1 levels, fasting glucose, HbA1c	Standard GH secretagogue panel; IGF-1 monitoring is non-negotiable

Preparation and Storage

Brand Egrifta is supplied as a lyophilized powder with sterile diluent for reconstitution per the prescribing information. The newer Egrifta WR formulation simplifies reconstitution with a water-reconstituted format. Research-grade tesamorelin follows standard lyophilized peptide reconstitution with bacteriostatic water.

Storage: 2–8°C (35–46°F) for lyophilized powder. Reconstituted solution is stable for up to 28 days when refrigerated. Do not freeze reconstituted solution. Standard subcutaneous injection technique applies, with abdomen as the preferred injection site per prescribing information.

For detailed reconstitution protocols, storage guidelines, and injection technique, see: How to Reconstitute Lyophilized Peptides, Peptide Storage and Handling, Injection Site Rotation Guide.

Frequently Asked Questions

Related Compounds: How Tesamorelin Compares

Tesamorelin sits in the Cluster A Weight Loss & Metabolic group alongside GLP-1 receptor agonists, dual/triple agonists, and other investigational metabolic compounds. Its mechanism is entirely different from the GLP-1 compounds — it works through the GH axis rather than the incretin axis. Within the broader GH secretagogue space, tesamorelin is the only FDA-approved GHRH analog. Understanding where it fits requires comparing both within its metabolic cluster and across the GH secretagogue landscape.

Semaglutide — GLP-1 receptor agonist. Entirely different mechanism (incretin axis, not GH axis). FDA-approved for T2D and obesity. ~15% weight loss at approved dose. Does not specifically target visceral fat via GH-mediated lipolysis.

Tirzepatide — Dual GLP-1/GIP receptor agonist. Different mechanism class. 22.5% weight loss at highest dose. FDA-approved for T2D, obesity, and OSA. Not comparable to tesamorelin on mechanism.

Retatrutide — Triple agonist (GLP-1/GIP/glucagon). Phase III. Different mechanism class entirely. The most aggressive weight loss results to date (~24% at 48 wk).

AOD-9604 — GH fragment (hGH 177-191). Related via GH axis but different mechanism: mimics GH’s lipolytic action without stimulating IGF-1 or full GH signaling. No FDA approval. Preclinical evidence only.

Sermorelin — GHRH(1-29) fragment. Most direct comparison to tesamorelin. Shorter sequence, shorter half-life, no FDA approval (previously approved, then discontinued). No Phase III data for body composition.

CJC-1295 (no DAC) — Modified GHRH(1-29) with amino acid substitutions. Same receptor target, different modification strategy. No FDA approval or Phase III data.

Ipamorelin — Selective GHS-R1a agonist. Different receptor (ghrelin receptor vs. GHRH receptor), different signaling pathway (Gq/Ca²+ vs. Gs/cAMP). Complementary to tesamorelin — commonly stacked in community protocols.

MK-677 (Ibutamoren) — Non-peptide oral GHS-R1a agonist. Continuous 24-hr GH stimulation (non-pulsatile). More sustained glucose elevation than tesamorelin. Oral route is convenient but the pharmacological profile is fundamentally different from pulsatile GHRH agonism.

Compound	Type	Primary Target	Half-Life	FDA Status	WADA Status	Evidence Tier	Weight Loss Efficacy	Route	Mechanism Class	Key Differentiator
Semaglutide	Synthetic GLP-1 receptor agonist peptide	GLP-1R	~7 days	FDA-approved (Wegovy, Ozempic)	Prohibited — S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics)	Tier 1 — Approved Drug	Up to 22% body weight reduction (Phase III)	Subcutaneous injection (weekly)	GLP-1 agonist	Longest half-life in class; once-weekly dosing. Identical sequence to human GLP-1 except for fatty acid moiety for albumin binding
Tirzepatide	Synthetic dual GLP-1R/GIPR agonist peptide	GLP-1R / GIPR	~5 days	FDA-approved (Zepbound, Mounjaro)	Prohibited — S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics)	Tier 1 — Approved Drug	Up to 22% body weight reduction (Phase III SURMOUNT-3)	Subcutaneous injection (weekly)	Dual GLP-1/GIP agonist	Dual agonism produces greater weight loss than GLP-1 monotherapy. Glucose-dependent mechanism
Retatrutide	Synthetic triple GLP-1R/GIPR/GcgR agonist peptide	GLP-1R / GIPR / GcgR	~5 days	Phase III clinical trials (not yet approved)	Prohibited — S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) — projected	Tier 2 — Clinical Trials (Phase III)	Up to 24% body weight reduction (Phase II)	Subcutaneous injection (weekly)	Triple GLP-1/GIP/glucagon agonist	Broadest receptor coverage in development. Glucagon pathway adds hepatic glucose production suppression
Liraglutide	Synthetic GLP-1 receptor agonist peptide	GLP-1R	~13 hours	FDA-approved (Saxenda, Victoza)	Prohibited — S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics)	Tier 1 — Approved Drug	Up to 8% body weight reduction (Phase III SCALE)	Subcutaneous injection (daily)	GLP-1 agonist	First GLP-1 RA approved for weight management. Daily dosing. Well-established long-term safety data
Orforglipron	Non-peptide small-molecule GLP-1 receptor agonist	GLP-1R	~11 hours	FDA-approved (Foundayo)	Prohibited — S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics)	Tier 1 — Approved Drug	Up to 15% body weight reduction (Phase II interim)	Oral (small molecule)	GLP-1 agonist (oral)	First oral non-peptide GLP-1 RA approved for weight management. Room-temperature stable, no injection required
CagriSema	Synthetic fixed-ratio combination (semaglutide + cagrilintide)	GLP-1R / AmylinR	~7 days (semaglutide) / ~7 days (cagrilintide)	Phase III clinical trials (pending)	Prohibited — S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) — projected	Tier 2 — Clinical Trials (Phase III)	Up to 20% body weight reduction (Phase II interim)	Subcutaneous injection (weekly)	GLP-1/amylin dual agonist	Combines GLP-1 RA with long-acting amylin analog. Amylin pathway targets satiety and gastric emptying synergistically
Survodutide	Synthetic dual GLP-1R/GcgR agonist peptide	GLP-1R / GcgR	~3–4 days	Phase II clinical trials (pending)	Prohibited — S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) — projected	Tier 2 — Clinical Trials (Phase II)	Up to 18% body weight reduction (Phase II interim)	Subcutaneous injection (weekly)	GLP-1/glucagon dual agonist	Glucagon pathway without GIP agonism. May offer weight loss with reduced nausea vs. triple agonists
AOD-9604	Modified fragment of GH (amino acids 177–191)	GH mimetic (fragment-based)	~2–4 hours	Not FDA-approved	Prohibited — S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) — as GH fragment	Tier 3 — Pilot / Limited Human Data	~2–3% body weight reduction (limited human data)	Subcutaneous injection	GH C-terminus analog (lipolytic)	Smaller peptide (15 amino acids) derived from GH. Lipolytic effect without GH-typical muscle anabolism claims
5-Amino-1MQ	Synthetic small molecule quinone metabolite analog	NNMT inhibitor	~6–8 hours	Not FDA-approved	Not WADA-listed — emerging research compound	Tier 4 — Preclinical Only	~5–8% body weight reduction (mouse models only; limited human data)	Oral (small molecule)	NNMT inhibition (NAD+ pathway)	Non-peptide. Targets mitochondrial NAD+ metabolism. No human safety/efficacy data published
MOTS-c	Synthetic mitochondrial open-reading-frame peptide (13 amino acids)	AMPK activator (AMP-kinase pathway)	~2–4 hours	Not FDA-approved	Prohibited — S0 (Non-Approved Substances)	Tier 4 — Preclinical Only	Modest weight reduction (animal models); no published human trials	Subcutaneous injection	Mitochondrial-derived peptide analog	Endogenous mitochondrial peptide. Activates AMPK/SIRT pathway. Only mouse models published
Tesamorelin	Synthetic GHRH analog (1-44 amino acids, GHRH-analogue with acyl modification)	GHRH-R	~26 minutes	FDA-approved (Egrifta for lipodystrophy in HIV)	Prohibited — S2 (GHRH analog)	Tier 1 — Approved Drug	~2–4% visceral fat reduction (HIV lipodystrophy indication)	Subcutaneous injection (daily)	GHRH analog	Only GH secretagogue approved by FDA for visceral adiposity. Raises GH indirectly via pituitary. Limited weight loss data in non-HIV populations

Summary and Key Takeaways

Tesamorelin is the only FDA-approved growth hormone-releasing hormone analog, and its evidence base sets it apart from every other compound in the GH secretagogue class. The approved indication — HIV-associated lipodystrophy — is backed by two Phase III randomized controlled trials with over 800 participants, objective CT-measured endpoints, and more than fifteen years of post-marketing surveillance. That is a level of evidence that no other GHRH analog, ghrelin mimetic, or GH secretagogue can match.

The expanding research into NAFLD and cognitive function adds meaningful depth to the tesamorelin story. The NAFLD data (Stanley 2019) showed a 37% relative reduction in hepatic fat with fibrosis prevention — Phase II quality, but mechanistically supported by transcriptomic analysis. The cognitive data (Baker 2012) is unique in this cluster: a non-HIV population, robust executive function improvements, and a coherent neurochemical mechanism through GABA modulation. Both lines of research warrant Phase III follow-up.

The honest gap in the evidence is the one most relevant to off-label users: no published RCT exists for tesamorelin in non-HIV adults seeking body composition improvement. The mechanism should work, and clinical observation supports it, but the controlled trial data has not yet been generated. That gap deserves acknowledgment, not avoidance.

The safety profile is well-characterized and monitorable: glucose impairment (5% at HbA1c ≥6.5%), IGF-1 elevation (requires monitoring, discontinuation if persistently >3 SDS), fluid retention, and injection site reactions. These are known quantities with established monitoring protocols — a significant advantage over compounds with no safety data at all.

Verdict Recapitulation

FDA-approved for HIV lipodystrophy with robust Phase III evidence. Phase II data extends the story into NAFLD and cognitive function. The only GHRH analog with regulatory validation. Safety profile is well-characterized and monitorable. Off-label use for non-HIV body composition is widespread but ahead of the published evidence base.

Where to Source Tesamorelin

Brand Egrifta is available by prescription for the approved indication. Off-label prescriptions can be filled through compounding pharmacies operating under 503A/503B rules. Research-grade tesamorelin is available from peptide vendors but is not subject to pharmaceutical quality standards. See the Peptidings sourcing guide for general principles on evaluating peptide quality.

Further Reading and Resources

If you want to go deeper on tesamorelin, the evidence landscape for growth hormone secretagogues and metabolic peptides, or the methodology behind how we evaluate this research, these are the places worth your time.

On Peptidings

• Sermorelin: What the Research Actually Shows — GHRH(1-29) fragment, the most direct comparator.
• CJC-1295 (no DAC): What the Research Actually Shows — Modified GHRH(1-29), same receptor target.
• Ipamorelin: What the Research Actually Shows — GHS-R1a agonist, commonly stacked with tesamorelin.
• MK-677: What the Research Actually Shows — Oral non-peptide GH secretagogue.
• Weight Loss & Metabolic Cluster Hub — All compounds in this category.
• Evidence Levels Explained — Peptidings’ tier system.
• Half-Lives and Dosing — Why dosing frequency matters.
• How to Reconstitute Lyophilized Peptides — Step-by-step reconstitution guide.

External Resources

• PubMed — Biomedical Research Database — Search for “tesamorelin” or related terms.
• ClinicalTrials.gov — Check for registered or ongoing trials.

Selected References and Key Studies

1. Falutz J, et al. “Metabolic effects of a growth hormone–releasing factor in patients with HIV.” N Engl J Med. 2007;357(23):2359–70. PubMed
2. Falutz J, et al. “Effects of tesamorelin (TH9507) in HIV-infected patients with excess abdominal fat.” J Acquir Immune Defic Syndr. 2010;53(3):311–22. PubMed
3. Stanley TL, et al. “Effects of tesamorelin on non-alcoholic fatty liver disease in HIV.” Lancet HIV. 2019;6(12):e821–e830. PubMed
4. Baker LD, et al. “Effects of growth hormone–releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults.” Arch Neurol. 2012;69(11):1420–9. PubMed
5. Baker LD, et al. “Growth hormone-releasing hormone effects on brain GABA levels in mild cognitive impairment and healthy aging.” Alzheimers Dement. 2013. PubMed
6. Erlandson KM, et al. “Tesamorelin decreases muscle fat and increases muscle area in adults with HIV.” J Frailty Aging. 2019;8(3):153–155. PubMed
7. Stanley TL, et al. “Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD.” JCI Insight. 2020;5(15):e140134. PubMed
8. Spooner LM, Olin JL. “Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy.” Ann Pharmacother. 2012;46(2):240–7. PubMed
9. Bedimo R. “Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy.” HIV AIDS (Auckl). 2011;3:69–79. PubMed
10. Dhillon S. “Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy.” Drugs. 2011;71(8):1071–91. PubMed
11. Stanley TL, et al. “Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation.” JAMA. 2014;312(4):380–9.
12. Fourman LT, et al. “Delineating tesamorelin response pathways in HIV-associated NAFLD using a targeted proteomic and transcriptomic approach.” Sci Rep. 2021.
13. Fourman LT, et al. “Effect of tesamorelin in people with HIV with and without dorsocervical fat.” J Clin Transl Sci. 2023. PMC9947601.
14. Meta-analysis: “Body composition, hepatic fat, metabolic, and safety outcomes of tesamorelin in HIV-associated lipodystrophy.” 2025. PubMed
15. Egrifta (tesamorelin) prescribing information. Theratechnologies Inc. FDA NDA 022505 (2025 label).
16. Egrifta SV prescribing information. FDA 2019 label.
17. FDA clinical pharmacology review, NDA 022505.
18. WADA 2026 Prohibited List. S2 — Peptide Hormones.
19. Falutz J. “Therapy insight: body composition changes and metabolic complications associated with HIV and HAART.” Nat Clin Pract Endocrinol Metab. 2007.
20. Hadigan C, et al. “Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin.” Clin Infect Dis. 2012;54(11):1642–51. PubMed